The scientists implanted
the human glioblastomas inside the brains of mice, then injected the
experimental virus directly into the tumors.
Untreated mice died in 19
days, but 60 percent of the treated mice were alive and thriving for
four months. Healthy tissue nearby remained unharmed.
Scientists euthanized the
survivors to see what was happening inside their brains and found
only empty cavities and scar tissue where the tumors once were.
"Everyone here is excited
about it because we've never seen anything happen with the mice like
that," says lead researcher Dr. Frederick Lang, a neurosurgeon at
Houston's M.D. Anderson Cancer Center.
He cautioned that the
dramatic results don't assure the virus will work in people:
Scientists have cured lots of mice of cancer only to see the
therapies fail in patients.
"This is an interesting
study," said Dr. Len Lichtenfeld of the American Cancer Society (news
-
web sites). But he echoed Lang's caution, adding that mutant
viruses could prove too toxic to use.
"We need to be very, very
careful" in studying the experimental treatment, Lichtenfeld said.
"There are too many situations where doctors and patients and
families have gotten very, very excited about drugs and it's turned
out ... that the drugs weren't effective. We need to avoid that."
Still, the National
Cancer Institute (news
-
web sites) is intrigued enough that it is providing $1 million
to produce enough of the mutant virus to begin human testing, said
Lang, who hopes to start enrolling brain-tumor patients in a study
of the treatment by winter 2004.
The virus should target
other solid tumors, too, he said.
But "if there's any
disease that needs a novel approach, it's really brain tumors," said
Lang, who reported the experiment in this week's Journal of the
National Cancer Institute.
Glioblastomas are the
most common primary brain tumor in adults, striking about 7,000
Americans a year, and the most lethal. Survival is only about a
year, a dismal rate that hasn't changed in decades despite
improvements in surgery and radiation and chemotherapy treatments.
A question is whether
people's immune systems will attack the mutant virus before it can
penetrate and spread through a brain tumor. The virus would have to
be injected through the skull directly into the brain tumor, which
could delay the immune reaction.
"It's going to be a
race," Lang said. But "our studies suggest that there's a certain
window of time between the immune system gearing up and the virus
being stopped."